Craif
Craif Closes Approximately $33M Series D for Urine-Based Cancer Test
Craif announced $33M in Series D financing on August 18, 2026. Craif closed an approximately $33 million Series D, made up of about $30.7 million in equity and about $3.3 million in debt and co-led by Granite-Integral and Tauns Co., Ltd., bringing total capital raised to roughly $88 million.
Round details
The financing includes backing from Granite-Integral, Tauns Co., Ltd., Unreasonable, X&KSK. The company did not publish a valuation with the announcement.
- Round: Series D
- Capital announced: $33M
- Total funding reported: $88M
- Headquarters: Tokyo, Japan
How the company plans to use the capital
Craif said it will use the proceeds to strengthen its U.S. R&D, prepare for a reimbursement-driven launch of its non-invasive cancer test in the United States, and advance its Japanese regulatory filing for a software-based medical device program targeting pancreatic cancer diagnosis.
Why this matters for GTM teams
Craif, a bio-AI company founded in Japan in 2018, opened a bio-AI laboratory in San Diego in April 2026 and says it is preparing a reimbursement-driven U.S. launch of its non-invasive cancer test.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Craif Series D announcement.
Company Info
Investors (4)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started